Ordinary Submission – PACTRIMS 2018

Poster Number Topic Abstract Title Author Country
P-1 MS: Epidemiology, Clinical Study, and Care Decreased Rice Intake is a Unique Risk Factor for Multiple Sclerosis in Japanese People in Addition to Smoking, Earlier Menarche, and Low Sunlight Exposure in Childhood Sakoda Ayako Japan
P-2 MS: Epidemiology, Clinical Study, and Care Three dietary patterns consistently demonstrated over five years of follow-up in early multiple sclerosis: results from the AusLong Study Steve Simpson, Jr. Australia
P-3 MS: Epidemiology, Clinical Study, and Care Multiple sclerosis registry-our experience M A Kanikannan India
P-4 MS: Epidemiology, Clinical Study, and Care Associations of demographic and clinical factors with positive depression-screen over 2.5-years in an international prospective cohort of people living with multiple sclerosis Steve Simpson, Jr. Australia
P-5 MS: Epidemiology, Clinical Study, and Care Health Outcomes and Lifestyle In a Sample of People with Multiple Sclerosis (HOLISM): longitudinal and validation cohorts Steve Simpson, Jr. Australia
P-6 MS: Epidemiology, Clinical Study, and Care Mastery is significantly associated with greater physical and mental health-related quality of life in two independently recruited international samples of people with multiple sclerosis Steve Simpson, Jr. Australia
P-7 MS: Epidemiology, Clinical Study, and Care Pathological Laughter in a Patient with Multiple Sclerosis Joong-Yang Cho Republic of Korea
P-8 MS: Epidemiology, Clinical Study, and Care Syntactic Complexity in Iranian Individuals with Relapsing- Remitting Multiple Sclerosis Sara Yazdani Iran
P-9 MS: Epidemiology, Clinical Study, and Care Cognitive Deficit, Affective Disorders and Fatigue in Malaysian Multiple Sclerosis Patients Joyce Pauline Joseph Malaysia
P-10 MS: Epidemiology, Clinical Study, and Care Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients with Relapsing–Remitting Multiple Sclerosis Rajesh Bakshi Switzerland
P-11 MS: Epidemiology, Clinical Study, and Care Singapore Neuroimmunology Rounds – Developing a Community of Practice for the care of Multiple Sclerosis, Neuromyelitis Optica and Neuroimmune conditions Simon Ling Singapore
P-12 MS: Epidemiology, Clinical Study, and Care Cerebral Cortical Thickness Changes in Neuro-Behçet’s Disease Kim Kyoung Woo Republic of Korea
P-13 MS: Epidemiology, Clinical Study, and Care Expanded Nurse-led Services for Neuroimmunology Patients in a Tertiary Centre Siew Noi Janis Tye Singapore
P-14 MS: Laboratory Study Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as potential biomarkers for disease activity and disability in neuromyelitis optica spectrum disorders and multiple sclerosis Mitsuru Watanabe Japan
P-15 MS: Laboratory Study Neurofilament Light Levels in the Blood of Patients with Secondary Progressive MS are Higher Than in Primary Progressive MS and may Predict Brain Atrophy in Both MS Subtypes David Leppert Switzerland
P-16 MS: Laboratory Study Longitudinal Analysis of Serum Neurofilament Light Chain:  A Potential Therapeutic Monitoring Biomarker for Multiple Sclerosis Hyun Jae-Won Republic of Korea
P-17 MS: Laboratory Study Increased plasma-borne extracellular vesicles in Multiple Sclerosis – Where did they come from? Kira Groen Australia
P-18 MS: Laboratory Study Identifying the role of Factor VIII and Von Willebrand factor in multiple sclerosis Kaibin Shi USA
P-19 MS: Laboratory Study The risk of Celiac disease in patients with Relapse-Remitting Multiple Sclerosis with increased TTG6 serum levels Sepideh Allahdadian Iran
P-20 MS: Laboratory Study Vitamin D levels in inpatients from a Victorian Tertiary hospital: seasonal trends and levels over time. Mastura Monif Australia
P-21 MS: Laboratory Study Serum Anti-JCV Antibody Status in Western Australian Patients With Multiple Sclerosis Marzena Pedrini Australia
P-22 MS: Laboratory Study HLA-DRB1*15:01 Protects and DR4 Facilitates JCV Infection in Japanese Patients with Multiple Sclerosis Yuri Nakamura Japan
P-23 MS: Laboratory Study New approach to old data: machine learning algorithm identifies KiR-HLA gene associations in MS and potential differences in subtype. Sean Burnard United Kingdom
P-24 MS: Laboratory Study Genome-wide DNA Methylation in Secondary Progressive Multiple Sclerosis Patients Reveals Unique Epigenetic Signature Vicki Maltby Australia
P-25 MS: Laboratory Study The role of APOE polymorphism on cognitive impairment in patients with inflammatory demyelination diseases in CNS Lan Chu China
P-26 MS: Laboratory Study The Correlation of Optical Cohorence Tomography Findings with Serum Cytokine Levels, TNF-α, Serum Neopterin Levels in Relapsing and Remitting Periods of MS Hakan Ekmekci Turkey
P-27 MS: Laboratory Study The Importance Value of Contrast Sensitivity  in Multiple Sclerosis without Prior Optic Neuritis Ni Nengah Ariarini Indonesia
P-28 MS: Laboratory Study Transorbital ultrasonography in acute optic neuritis: can it be a supportive diagnostic tool? Ye-Ji Kwon Republic of Korea
P-29 MS: Laboratory Study A Comparison of Clinical Manifestations of Idiopathic Optic Neuritis in Asian and Western Patients Manyong Lee Republic of Korea
P-30 MS: MRI Study Investigating the Mechanisms of Microstructural and Functional Changes in the Motor Pathway in Multiple Sclerosis Justin Garber Australia
P-31 MS: MRI Study The Contribution of Subcortical Structures to Memory Impairment in Multiple Sclerosis Devenney Emma Australia
P-32 MS: MRI Study Filling in the Gaps: Precision Magnetic Resonance Imaging Reporting in Multiple Sclerosis Clinical Practice Heidi Beadnall Australia
P-33 MS: MRI Study Exploring the Influence of Quantitative Magnetic Resonance Imaging on Decision Making in Multiple Sclerosis Clinical Practice Heidi Beadnall Australia
P-34 MS: MRI Study Quantitative Susceptibility Mapping in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Woojun Kim Republic of Korea
P-35 MS: MRI Study Segmentation of White Matter and Detection of Lesions with Machine Learning Hafiz Muhammad Rehan Afzal Australia
P-36 MS: MRI Study Quantitative evaluation of cervical spine damage in MS patients and its correlation with EDSS by using diffusion tensor MR imaging Roya Abolfazli Iran
P-37 MS: MRI Study Brain volume loss can predict cognitive impairments by neuropsychological battery in a cross-sectional study of Chinese patients with multiple sclerosis Alexander Yuk Lun Lau China
P-38 MS: MRI Study Increasing Baseline Brain MRI Lesion Numbers and Intrathecal B cell Responses in Korean Multiple Sclerosis Patients with Adult-Onset Hyun-June Shin Republic of Korea
P-39 MS: MRI Study Brain Atrophy is Associated with Higher Serum Amyloid A Levels in Patients with Relapsing and Remitting Multiple Sclerosis and Clinically Isolated Syndrome

Hiroaki Yokote

P-40 MS: MRI Study Evaluation of metabolic alterations in the MS brain using fast Spiral MRSI and machine learning Oun Al-iedani Australia
P-41 MS: MRI Study q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with glatiramer acetate Kenji Kufukihara Japan
P-42 MS Treatment: Dimethyl Fumarate Safety of Dimethyl Fumarate in Japanese Patients with Relapse-remitting MS for 72 Weeks in the APEX Part 1 and Part 2 Studies Hirofumi Ochi Japan
P-43 MS Treatment: Dimethyl Fumarate The Interim Sub-analysis from APEX Part 1+2 Studies; Efficacy and Safety of Dimethyl Fumarate in Treatment-naïve Japanese Patients with Relapse-remitting MS Masahiro Mori Japan
P-44 MS Treatment: Dimethyl Fumarate Efficacy of Dimethyl Fumarate in Japanese MS Patient in Phase 3 APEX Study and the Open Label Extension Study: 72 weeks Interim Analysis Takayuki Kondo Japan
P-45 MS Treatment: Dimethyl Fumarate Efficacy and Safety of Dimethyl Fumarate in Japanese MS Patients Who had the History of Treatment with Fingolimod: APEX Part 1+2 Interim Analysis Kazumasa Yokoyama Japan
P-46 MS Treatment: Dimethyl Fumarate Transient Bone Marrow Oedema Syndrome following Dimethyl Fumarate use. Allan Kermode Australia
P-47 MS Treatment: Fingolimod Comparable Rates of Longitudinal Grey Matter Atrophy in Relapsing Multiple Sclerosis Patients Treated with Fingolimod and Healthy Controls Using Magnetic Resonance Imaging Analysis Techniques Heidi Beadnall Australia
P-48 MS Treatment: Fingolimod Functional Immune-phenotyping in Fingolimod-treated Multiple Sclerosis Patients: Assessing Drug Effects and Treatment Response Biomarkers Mahtab Ghadiri Canada/Australia
P-49 MS Treatment: Fingolimod Retrospective, Non-interventional, Multi-centre Study Evaluating Safety of Fingolimod in Patients with Multiple Sclerosis in Taiwan Chih-chao Yang Taiwan
P-50 MS Treatment: Fingolimod Synthesis and Development of Novel Compounds Selectively Targeting on Sphingosine 1-Phosphate Receptor 1 (S1P1) for Treatment of Multiple Sclerosis Ki Duk Park Republic of Korea
P-51 MS Treatment: Fingolimod Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis from the BOLD and EXPAND Trial and their Extensions Rajesh Bakshi Switzerland
P-52 MS Treatment: Fingolimod Chronic HPV associated lesions associated with Fingolimod use Allan Kermode Australia
P-53 MS Treatment: Alemtuzumab Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) Pamela McCombe Australia
P-54 MS Treatment: Alemtuzumab Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS II Follow-up (TOPAZ Study) Simon Broadley Australia
P-55 MS Treatment: Alemtuzumab Additional Courses of Alemtuzumab Improved Clinical and MRI Outcomes in Pooled CARE-MS I and II Patients With Disease Activity After Two Courses: Analysis of Patients Who Received >=3 Courses Ho Jin Kim Republic of Korea
P-56 MS Treatment: Alemtuzumab Alemtuzumab in The Treatment of Relapsing-Remitting Multiple Sclerosis (MS): Real World Experience from Singapore Amy May Lin Quek Singapore
P-57 MS Treatment: Alemtuzumab Improvements Across Functional Systems Are Maintained Regardless of Early vs Late Confirmed Disability Improvement: CARE-MS 6-Year Follow-up Richard Macdonell Australia
P-58 MS Treatment: Alemtuzumab Treatment outcome of alemtuzumab in Korean patients with multiple sclerosis: 2 years follow-up Hyun Jae-Won Republic of Korea
P-59 MS Treatment: Alemtuzumab Multiple autoimmune complications in three Alemtuzumab treated patients: a single centre experience Blake Giarola Australia
P-60 MS Treatment: Cladribine An Exploratory Analysis of the Efficacy of Cladribine Tablets 3.5 mg/kg in Patients with Relapsing Multiple Sclerosis Stratified According to Age Above and Below 45 Years in the CLARITY Study John King Australia
P-61 MS Treatment: Cladribine CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo John King Australia
P-62 MS Treatment: Cladribine Durability of NEDA-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: CLARITY Extension Dominic Jack Germany
P-63 MS Treatment: Cladribine Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline Dominic Jack Germany
P-64 MS Treatment: Cladribine Lymphopenia Rates in CLARITY/CLARITY Extension Are Unrelated to Disease Activity at Baseline Dominic Jack Germany
P-65 MS Treatment: Cladribine Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis John King Australia
P-66 MS Treatment: Cladribine The MAGNIFY-MS study: Mavenclad Tablets in Active RMS Jason Burton Australia
P-67 MS Treatment: Cladribine Cladribine modulates the expression of ICAM-1 and VCAM-1 on human brain endothelium; relevance to multiple sclerosis (MS) Simon Hawke Australia
P-68 MS Treatment: Other Drugs Patients’ Perspectives on a Changed Model of Care from Out-patients to The Home for the Infusion of Natalizumab Mahasen Juaton Australia
P-69 MS Treatment: Other Drugs Safety and Effectiveness in the 3rd Year Interim Results of All-Case Surveillance for Natalizumab in Japan Kazumasa Yokoyama Japan
P-70 MS Treatment: Other Drugs Long-term treatment with natalizumab in paediatric multiple sclerosis Radomir Talab Czech Republic
P-71 MS Treatment: Other Drugs How Anti-JCV Serostatus Affected Patient Selection, Safety, and Effectiveness of Natalizumab in Japan Takahiko Saida Japan
P-72 MS Treatment: Other Drugs Long-Term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials Richard Macdonell Australia
P-73 MS Treatment: Other Drugs Evaluation of Long-Term Treatment of Teriflunomide on Cognitive Outcomes and Association with Brain Volume Change: Data From the TEMSO Study and its Extension Jeannette Lechner-Scott Australia
P-74 MS Treatment: Other Drugs A Tertiary Centre Experience on short term teriflunomide treatment outcome on Relapse Remitting Multiple Sclerosis(RRMS) Shahedah Koya Kutty Malaysia
P-75 MS Treatment: Other Drugs Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data Pamela McCombe Australia
P-76 MS Treatment: Other Drugs Baseline Characteristics of the ENSEMBLE Study Population: A Phase IIIb Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis William Carroll Australia
P-77 MS Treatment: Other Drugs Real World Evidence (RWE) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (DMTs) in Relapsing-Remitting Multiple Sclerosis (RRMS) in Australia Helmut Butzkueven Australia
P-78 MS Treatment: Other Drugs Differential multiple sclerosis treatment allocation between Australia & New Zealand associated with clinical outcomes but not mood or quality of life Steve Simpson, Jr. Australia
P-79 MS Treatment: Other Drugs How Steroid Treatment Affects Neutrophil/Lymphocyte Ratio and Neutrophil/Thrombocyte Ratio in Multiple Sclerosis Sevki Sahin Turkey
P-80 NMOSD: Clinical Study The Prevalence of Neuromyelitis Optica Spectrum Disorder in Korea; Using National Health Insurance Claim Database Hye Lim Lee Republic of Korea
P-81 NMOSD: Clinical Study Clinical features of seropositive NMOSD without optic neuritis and myelitis in Japan Katsuichi Miyamoto Japan
P-82 NMOSD: Clinical Study Clinical presentation and outcome in pediatric neuromyelitis optica spectrum disorder: South China Report Yifan Zhou China
P-83 NMOSD: Clinical Study Neuromyelitis optica spectrum disorders with and without connective tissue disorders Yang Chun-Sheng China
P-84 NMOSD: Clinical Study Neuromyelitis optica spectrum disorder with vertigo or dizziness Wang Yanqiang China
P-85 NMOSD: Clinical Study Pneumonias in Neuromyelitis optica spectrum disorders Bingjun Zhang China
P-86 NMOSD: Clinical Study The Prevalence of Epilepsy in Patients With Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD) in Multi-ethnic Malaysia : A Long Term 16 Years Study. Sow Kuan Tee Malaysia
P-87 NMOSD: Laboratory Study Comparison of VEP Parameters in NMOSD and MS Patients Nilda Turgut Turkey
P-88 NMOSD: Laboratory Study Cervical and Ocular Vestibular-evoked Myogenic Potentials in Patients with Neuromyelitis Optica Spectrum Disorders Sun-Young Oh Republic of Korea
P-89 NMOSD: Laboratory Study Autonomic Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders Soonwook Kwon Republic of Korea
P-90 NMOSD: Laboratory Study Elevated soluble syndecan-1 levels in neuromyelitis optica are associated with disease severity Wang Honghao China
P-91 NMOSD: Laboratory Study Epstein-Barr Virus Induced G-protein Coupled Receptor 2 (GPR 183) Expression of B Cells and Serum IL-6 as Risk Factors of Relapse in Neuromyelitis Optica Spectrum Disorders with Aquaporin-4 IgG Seol-Hee Baek Republic of Korea
P-92 NMOSD: Laboratory Study The relevance of cerebrospinal fluid polymorphonuclear leukocytes in diagnosis of inflammatory CNS diseases Hiroshi Kuroda Japan
P-93 NMOSD: Treatment Precision Therapy for Neuromyelitis Optica Spectrum Disorder: A Retrospective Analysis of the Use of Class-Switched Memory B-cells for Individualized Rituximab Dosing Schedules Benjamin Trewin Australia
P-94 NMOSD: Treatment Conducting a Global Randomized Controlled Clinical Trial in Neuromyelitis Optica Spectrum Disorder – Continuous Uphill Challenges Ho Jin Kim Republic of Korea
P-95 NMOSD: Treatment Memantine and pioglitazone ameliorate motor impairments and complement-independent cord pathologies in mice received aquaporin-4 autoantibodies from neuromyelitis optica spectrum disorder (NMOSD) patients. Koon Ho Chan China
P-96 NMOSD: Treatment Relapse After Cessation Or Un-treatment Of Immunosuppressants In Neuromyelitis Optica Spectrum Disorder With Long-term Remission MinSu Park Republic of Korea
P-97 MOG Antibody Disease Clinical features of myelin oligodendrocyte glycoprotein-antibody+ disease: a study of 369 Japanese cases. Kimihiko Kaneko Japan
P-98 MOG Antibody Disease Myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination: comparison between onset phenotypes Yifan Zhou China
P-99 MOG Antibody Disease Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies Sung Min Kim Republic of Korea
P-100 MOG Antibody Disease Seizures in Chinese Patients with Myelin Oligodendrocyte Glycoprotein Encephalomyelitis:a retrospective study in single center Xiaonan Zhong China
P-101 MOG Antibody Disease Perivenous Inflammatory Demyelination with Myelin Oligodendrocyte Glycoprotein (MOG)-dominant Myelin Loss and CD4-dominant T cell Infiltration is Prominent in MOG Antibody-associated Disease Yoshiki Takai Japan
P-102 Animal Model Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in Multiple Screlosis mouse models Keisuke Yoshikawa Japan
P-103 Animal Model Antioxidant and anti-inflammatory effect of Sulforaphane in mice with experimental autoimmune encephalomyelitis Suk-Won Ahn Republic of Korea
P-104 Animal Model A novel single-chain variable fragment specific to C5 ameliorates a mouse model of neuromyelitis optica spectrum disorder Yaping Yan China
P-105 Animal Model Astrocytic interleukin-15 reduces pathology of neuromyelitis optica in mice Li Minshu China
P-106 Case Report: MS How long do the patients with radiologically-isolated syndrome (RIS) need a follow-up visit ? Sujin Lee Republic of Korea
P-107 Case Report: MS Two Cases of Radiologically Isolated Syndrome Hyung Jun Park Republic of Korea
P-108 Case Report: MS Case report vertigo as the first clinical manifestation of Multiple sclerosis Wang Yuge China
P-109 Case Report: MS Longitudinally Extensive Transverse Myelitis in a Patient with Highly Active Relapsing-Remitting Multiple Sclerosis Chen Fei Ng Malaysia
P-110 Case Report: MS Association of MS and IBD (Inflammatory Bowel Disease) – Case Series – A Therapeutic Predicament for Clinicians Neha Nandal Australia
P-111 Case Report: MS Natalizumab Related PML in a Low-Risk Patient: When “Low Risk” is Not “No Risk” Erin Kelly Australia
P-112 Case Report: MS Bullous pemphigoid after interferon beta-1a therapy in Multiple Sclerosis: complication or coincidence? Shahedah Koya Kutty Malaysia
P-113 Case Report: MS Effective Management of Trigeminal Neuralgia with Mandibular Nerve Block and Natalizumab in a Patient with Multiple Sclerosis Ryohei Norioka Japan
P-114 Case Report: NMOSD Asymptomatic spinal cord lesion in Neuromyelitis Optica Spectrum Disorder – A Case Report Hye-Jin Cho Republic of Korea
P-115 Case Report: NMOSD Relapse of neuromyelitis optica spectrum disorder mimicking an acute stroke-like onset presented with intractable hiccup and acute visual loss Wang Yuge China
P-116 Case Report: NMOSD Neuromyelitis optica spectrum disorder presenting as acute storke and callosal arch bridge involvement in brain magnetic resonance imaging: a case report Omid Mirmosayyeb Iran
P-117 Case Report: NMOSD A patient diagnosed as neuromyelitis optica with radiologically prominent tumefactive lesion Yool-hee Kim Republic of Korea
P-118 Case Report: NMOSD Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy presenting with mental change Bum Chun Suh Republic of Korea
P-119 Case Report: NMOSD A little-known new brain imaging feature in a patient with longstanding neuromyelitis optica spectrum disorder: leukodystrophy-like pattern Jun Seok Lee Republic of Korea
P-120 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 antibody mimicking with Longitudinal extensive transverse myelitis due to Neurosarcoidosis Young-Do Kim Republic of Korea
P-121 Case Report: NMOSD Limbic Encephalitis-Like Presentation In Neuromyelitis Optica Spectrum Disorder – A Case Report Jin Myoung Seok Republic of Korea
P-122 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder Presenting with Orthostatic Hypotension and Bilateral Ptosis Kok Pin Yong Singapore
P-123 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorders Associated with a Bacterial Infection Can Contribute to Devastating Course: A Case Report Wooryang Byun Republic of Korea
P-124 Case Report: NMOSD A Case of Concurrent Neuromyelitis Optica Spectrum Disorder and Demyelinating Neuropathy Sa-Yoon Kang Republic of Korea
P-125 Case Report: NMOSD Severe Longitudinally Extensive Transverse Myelitis Associated with Neurosarcoidosis in a Patient with Duropathy Takai Yasuyuki Japan
P-126 Case Report: NMOSD Myotonic Myopathy associated with Neuromyelitis Optica Spectrum Disorder Hyemi Lee Republic of Korea
P-127 Case Report: NMOSD Neuromyelitis optica spectrum disorder associated with herpes zoster:a case report Zhongping An China
P-128 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 6 Jae Young An Republic of Korea
P-129 Case Report: Other Allied Disorders Paraneoplastic Necrotizing Myelopathy Associated with Malignant Melanoma Taek-Jun Lee Republic of Korea
P-130 Case Report: Other Allied Disorders A case of longitudinally extensive transverse myelitis mimicking Guillain‐Barré syndrome Jung Im Seok Republic of Korea
P-131 Case Report: Other Allied Disorders Encephalitis and Acute Transverse Myelitis caused by Mycoplasma pneumoniae Ji Yeon Chung Republic of Korea
P-132 Case Report: Other Allied Disorders MOG-encephalomyelitis: two case reports on demyelinating pseudotumor Yaqing Shu China
P-133 Case Report: Other Allied Disorders Relapsing Optic Neuritis and Meningoencephalitis in a Child:Delayed diagnosis of MOG-IgG syndrome Xiaonan Zhong China
P-134 Case Report: Other Allied Disorders A case of acute disseminated encephalomyelitis mimicking multiple sclerosis attack O Anlar Turkey
P-135 Case Report: Other Allied Disorders A Young Patient with Recurrent Bilateral Optic Neuritis Jessica Tsz Ching Li China
P-136 Case Report: Other Allied Disorders A case of acute combined central and peripheral demyelination Chanik Park Republic of Korea
P-137 Case Report: Other Allied Disorders A Series of Unfortunate Events – A Case Study of Central Inflammatory Demyelination after Allogenic Stem Cell Transplant Arthur Thevathasan Australia
P-138 Case Report: Other Allied Disorders A case of white-eyed shunt carotid-cavernous sinus fistula mimicking optic neuritis Shintaro Hayashi Japan
P-139 Case Report: Other Allied Disorders Optic nerve metastasis mimicking optic neuritis Kyomin Choi Republic of Korea
P-140 Case Report: Other Allied Disorders Response to Immunosuppressive Therapy in Cerebral Amyloid Angiopathy-related Inflammation Benjamin Trewin Australia